Sermorelin

Research summary

Sermorelin is a 29-amino-acid fragment of growth hormone-releasing hormone that binds pituitary receptors and stimulates the pituitary to release its own growth hormone. It was originally FDA-approved as a diagnostic agent for growth hormone deficiency and studied clinically through the 1990s.

In published research, sermorelin produced a significant rise in growth hormone release and growth velocity in children with GH deficiency over six months of treatment. In separate trials in elderly adults with reduced IGF-1, sermorelin raised GH output, and one study reported improved performance on a cognitive test after six months. Human research on sermorelin is decades old and relatively limited in scale.

Sources: Clinical GH-secretagogue literature (JCSM Rapid Communications, 2020 review). Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.